Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoRecormon for anemia during peginterferon alfa plus ribavirin treatment of chronic hepatitis C
2007-003381-18Phase 4Active
- Sponsor
- Roche
- Start
- Aug 2007
- Modality
- Erythropoietins → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Interleukins → Cytokines & Interferons → Recombinant Proteins and Enzymes, Colony Stimulating Factors → Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of epoetin beta in Drug-induced hemolytic anemia (DIHA), sponsored by Roche. Primary endpoint: Clinical and laboratory safety at 6 months and 1 year. Started Aug 2007; status: active.
02
Drugs
epoetin beta
03
Conditions
Drug-induced hemolytic anemia (DIHA)
Beyond the preview
Go deeper on 2007-003381-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003381-18.